Surgery Partners Inc

Despite a persistent long-term downtrend and price below key moving averages, the chart’s Bearish Exhaustion pattern in an oversold context grants a medium-term bullish mean-reversion bias. Short-term execution lacks clear entry while price consolidates around the 9/20 EMAs, warranting patience and stalking pullbacks into the $13.80–$14.00 support zone ahead of a potential reversal bounce.

• ↑Analysts rate SGRY Moderate Buy with $19.45 PT, implying +37.8% upside
• ↑High earnings yield (~57%) suggests attractive valuation
• ↓Weak profitability metrics highlight margin and cash flow concerns